Hideyuki Katsura
Kanazawa University
PathophysiologyNephrotoxicityInternal medicinePathologyOncologyRetrospective cohort studyTumor necrosis factor alphaChemistryTissue factorHematologyIn vitroIn vivoHazard ratioLung cancerPerformance statusInflammationOsteosarcomaCisplatinOrgan dysfunctionDisseminated intravascular coagulationLipopolysaccharidePneumonitisNivolumabKidneyAdverse drug reactionCimetidineOxaliplatinRegimenPalliative careIncidence (epidemiology)Confidence intervalReactive oxygen speciesPharmacotherapyRisk factorColorectal cancerMedicinePharmacology
4Publications
2H-index
75Citations
Publications 4
Newest
#1Yukio Suga (Kanazawa University)H-Index: 10
#2Anna KuboH-Index: 1
Last. Hidesaku Asakura (Kanazawa University)H-Index: 33
view all 8 authors...
Lipopolysaccharide (LPS) and tissue factor (TF) have frequently been used to induce disseminated intravascular coagulation (DIC) in experimental animal models. We have previously reported that the pathophysiology of DIC differs according to the inducing agents. However, inflammatory status and bleeding symptoms have not been fully compared between rat models of the two forms of DIC. We attempted to evaluate detailed characteristic features of LPS- and TF-induced DIC models, especially in regard ...
Source
#1Hideyuki KatsuraH-Index: 1
#1Hideyuki KatsuraH-Index: 2
Last. Hiroki MaseH-Index: 1
view all 9 authors...
Background: Nivolumab efficacy in patients with non-small-cell lung cancer (NSCLC) and performance status (PS) of 2-4 is unclear. We aimed to compare survival, treatment efficacy, and safety in patients with NSCLC with poor PS who received nivolumab plus best supportive care (BSC) with those in patients who received BSC alone in a palliative care unit (PCU). Patients and methods: This retrospective study included 99 consecutive patients with NSCLC who received nivolumab plus BSC or BSC alone bet...
9 CitationsSource
#1Yukio Suga (Kanazawa University)H-Index: 10
#2Nana Ikeda (Kanazawa University)H-Index: 1
Last. Ryo Matsushita (Kanazawa University)H-Index: 11
view all 12 authors...
Vascular pain is a common adverse drug reaction in colorectal cancer patients receiving peripheral venous administration of oxaliplatin. The aim of this work was to identify risk factors for vascular pain, and to examine whether currently used treatments reduce its incidence. We conducted a multicenter retrospective study in Japanese colorectal cancer patients receiving peripheral venous administration of oxaliplatin. The effects of various treatments (administration of analgesics, addition of d...
2 CitationsSource
#1Hiromu Katsuda (Kanazawa University)H-Index: 1
#2Mariko Yamashita (Kanazawa University)H-Index: 1
Last. Ken-ichi Miyamoto (Kanazawa University)H-Index: 55
view all 8 authors...
The present study examined the influence of cimetidine on the nephrotoxicity and antitumor effects of cisplatin in vitro and in vivo. When the serum concentration of cimetidine was maintained over 20 μg/ml for 4 h by bolus and continuous intravenous infusion, cimetidine prevented nephrotoxicity of cisplatin without influencing antitumor activity. Cimetidine and the antioxidant N-acetylcysteine (NAC) significantly inhibited the in vitro growth inhibition of cisplatin in cells originating from the...
54 CitationsSource